Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [843]

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM...

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )

Evaluation of MRD negativity in patients with relapsed or refractory multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

$Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )$

Ponatinib, venetoclax and dexamethasone for patients with relapsed or...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

$Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )$

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL...

Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands

Clinical implications of MRD detection in infants with KMT2A-rearranged ALL Treated on the Interfant-06 protocol ( Dr Janine Stutterheim - Princess Máxima Center, Utrecht, Netherlands )

Predictive factors for overall survival in chronic myeloid leukaemia patients:...

Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )

Predictors of efficacy in patients with HR positive/HER2 negative ABC: Subgroup...

Prof Hope Rugo - University of California, San Francisco, USA

Predictors of efficacy in patients with HR positive/HER2 negative ABC: Subgroup analyses of PALOMA-3 ( Prof Hope Rugo - University of California, San Francisco, USA )

Using AI to examine muscle mass in brain tumour patients

Dr Matthew Williams - Imperial College London, London, UK

Using AI to examine muscle mass in brain tumour patients ( Dr Matthew Williams - Imperial College London, London, UK )

Interim results from a phase 1/2 precision medicine study of PLX8394- a next...

Dr Filip Janku - The University of Texas MD Anderson Cancer Center USA

Interim results from a phase 1/2 precision medicine study of PLX8394- a next generation BRAF inhibitor ( Dr Filip Janku - The University of Texas MD Anderson Cancer Center USA )

OncoAlert and ecancer weekly roundup for November 2 - 7, 2020

Dr Gil Morgan - Skåne University Hospital, Lund, Sweden

OncoAlert and ecancer weekly roundup for November 2 - 7, 2020 ( Dr Gil Morgan - Skåne University Hospital, Lund, Sweden )

Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of...

Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA

Bevacizumab-induced hypertension and proteinuria: A genome-wide analysis of more than 1,000 patients ( Prof Federico Innocenti - University of North Carolina, Chapel Hill, USA )

Critical issues in drug and biomarker development

Prof Tracy Lively - National Cancer Institute, USA

Critical issues in drug and biomarker development ( Prof Tracy Lively - National Cancer Institute, USA )

OncoAlert and ecancer weekly roundup for October 26 - 31, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for October 26 - 31, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer